Related Experiment Video
Updated: Jan 24, 2026

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Autologous cord blood in children with cerebral palsy: a review
Dariusz Boruczkowski1, Josep-Maria Pujal2, Izabela Zdolińska-Malinowska3
1Polski Bank Komórek Macierzystych S.A. (FamiCord Group), Jana Pawła II 29, 00-867 Warsaw, Poland. dariusz.boruczkowski@pbkm.pl.
Insights
Umbilical cord blood (CB) shows promise for diagnosing and treating cerebral palsy. Its biochemical makeup predicts neurodevelopment, and studies confirm the safety and efficacy of CB treatments.
Area of Science:
- Biomedical Science
- Regenerative Medicine
- Neuroscience
Background:
- Cerebral palsy (CP) is a significant neurological disorder.
- Umbilical cord blood (CB) contains valuable biological components.
- Current knowledge on CB's clinical applications requires synthesis.
Purpose of the Study:
- To review current knowledge on the clinical use of umbilical cord blood (CB).
- To explore CB's potential in early diagnostics and treatment of cerebral palsy.
- To assess the safety and efficacy of CB administration based on existing studies.
Main Methods:
- Narrative review of articles from PubMed.
- Analysis of clinical trials registered on ClinicalTrials.gov.
- Inclusion of a meta-analysis of five clinical trials.
Main Results:
- CB's biochemical parameters (cytokines, growth factors, metabolites) predict neurodevelopment.
- Clinical studies confirm the safety and efficacy of autologous and allogeneic CB administration.
- Nine ongoing clinical trials are evaluating autologous CB for hypoxic-ischemic encephalopathy and CP in over 2500 patients.
Conclusions:
- Umbilical cord blood (CB) holds significant potential for cerebral palsy diagnostics and treatment.
- The biochemical profile of CB is a key indicator for neurodevelopmental outcomes.
- Ongoing clinical trials are expanding the evidence base for CB therapies in neurological conditions.
Abstract:
The aim of this narrative review is to report on the current knowledge regarding the clinical use of umbilical cord blood (CB) based on articles from PubMed and clinical trials registered on ClinicalTrials.gov. An increasing amount of evidence suggests that CB may be used for both early diagnostics and treatment of cerebral palsy. The acidity of CB and its biochemical parameters, including dozens of cytokines, growth factors, and other metabolites (such as amino acids, acylcarnitines, phosphatidylcholines, succinate, glycerol, 3-hydroxybutyrate, and O-phosphocholine) are predictors of future neurodevelopment. In addition, several clinical studies confirmed the safety and efficacy of CB administration in both autologous and allogeneic models, including a meta-analysis of five clinical trials involving a total of 328 participants. Currently, nine clinical trials assessing the use of autologous umbilical CB in children diagnosed with hypoxic-ischemic encephalopathy or cerebral palsy are in progress. The total population assessed in these trials exceeds 2500 patients.
More Related Videos
08:24Author Spotlight: Exploring the Potential of Massage Therapy in Cerebral Palsy Using Animal Models
Published on: August 11, 2023
08:26Event-related Potentials During Target-response Tasks to Study Cognitive Processes of Upper Limb Use in Children with Unilateral Cerebral Palsy
Published on: January 11, 2016
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Drug Dosing: Infants and Children
Spinal Cord
Cerebral Hemispheres
The Spinal Cord